Leica Microsystems and A Menarini Diagnostics extend distribution agreement

7 August 2009

Leica Microsystems GmbH and A. Menarini Diagnostics S.r.l. have signed a five-year agreement to extend their successful co-operation in distributing Leica products in Europe.

According to this agreement, Menarini Diagnostics will continue to be the exclusive distributor in key European countries for Leica Microsystems’ automated immunohistochemistry (IHC) stainer, Leica Bond, as well as Leica Microsystems’ Novocastra antibodies and reagents.

The Leica BOND is a flexible, fully-automated staining system for immunohistochemistry-based cancer diagnosis. Used in combination with Leica Microsystems’ well-known range of Novocastra antibodies, it allows fast, reliable and consistent staining of tissue samples (biopsies) to aid in the diagnosis and staging of cancer.

The distribution agreement succeeds a five-year contract between the companies. “We are pleased to be able to continue our successful partnership with Menarini Diagnostics. This partnership will allow our joint customers to benefit from Menarini’s strong sales force and customer support and from our world-class immunohistochemistry products. This partnership is key to our goal to further increase our market share in immunohistochemistry in Europe,” explains Dr. David Martyr, President Leica Microsystems.

Dr. Crescenzio Izzo, Managing Director A. Menarini Diagnostics said: “The renewal of this agreement confirms our approach to build strong partnerships with customers and Leica Microsystems, a leading company in R&D and Manufacturing of innovative product solutions.

Our expert, specialized distribution organization covers a large part of the European diagnostics market. We have built our expertise in the Immunohistochemistry field for almost 20 years and we employ about 300 highly skilled people in sales, technical services and application support. Menarini takes its responsibility to the healthcare community seriously and strives to always provide the best solutions to its customers’ needs in the field of immunohistochemistry.”

Bookmark this page

To top